View experts by name

View by service and office location

Claus Andersen

Partner

T: 020 7842 1462 (DDI)
T: 020 7583 2222
E: claus.andersen@roydswithyking.com

Email Claus

Download contact

If you are having difficulty getting in touch with your contact then you can email enquiries@roydswithyking.com or call 0800 923 2073

Claus is a partner in our Corporate & Commercial and Life Sciences teams. He deals with all aspects of corporate and commercial work for corporate clients, limited companies, businesses, private individuals and trade organisations.

About Claus

Claus was admitted to the High Courts of Denmark and the Copenhagen Maritime and Commercial Court in 2003. In addition, he was admitted as a solicitor in England and Wales in February 2008 and became a partner at Royds LLP in August 2011.

Claus has substantial experience in areas including company law, commercial contracts and finance, with particular emphasis on shareholders agreements, distribution agreements, general commercial contracts, the Bribery Act 2010 and the Exemption rules of the FSMA (Financial Promotion) order.

Memberships

Claus is a member of the Danish Law Society.

The Legal 500 - The Clients Guide to Law Firms

 

Related articles

Opinion [4]
Article thumbnail

Brexit and the lawyer who cried wolf!

23 January 2020

When you cover Brexit, like I do, you cannot help feeling a bit like the proverbial ‘boy who cried wolf’. Over the past three and a half years, all of us dealing with Brexit in blogs, comments and seminars have said on numerous occasions that “Brexit was coming” – only for it to be delayed, over and over again. However, this time the wolf is real: Brexit is actually coming.

Read more..
Article thumbnail

Life Sciences Forum – a few reflexions

19 December 2019

On Thursday 14 November I attended a great event at the offices of Deutsche Bank hosted and organised by the Swedish Chamber of Commerce in London.

Read more..
Article thumbnail

Parliament goes blue. What’s in store for business?

13 December 2019

The speculation is over. What’s in store for businesses across the UK now?

Read more..
Article thumbnail

What the Queen said about Life Sciences

29 October 2019

Recent weeks have in the news been dominated by Brexit, the withdrawal agreement, the suspension of Parliament and in the end the Queen’s speech.

Read more..
See more articles in Opinion
News [4]
Article thumbnail

Departure of European Medicines Agency takes 40,000 London hotel rooms with it

21 November 2017

The EU yesterday (20 November) announced that the European Medicines Agency will relocate from its Docklands home to Amsterdam when the UK leaves the EU in 2019, taking with it around 1,000 high value jobs. The move will, says Royds …

Read more..

Court agrees to deal between business and fraud investigators

26 July 2016

The Serious Fraud Office (SFO) has this month announced a second deferred prosecution agreement which will see a firm pay more than £6million for corruption and bribery offences. The deal was reached between the unnamed company and SFO officials and …

Read more..

Politicians pledge to tackle corporate corruption

27 June 2016

The Prime Minister has outlined new plans to curb corruption in business. David Cameron set out proposals for sweeping reforms to coincide with the start of an international summit and commentators claim that the measures will eclipse those previously included …

Read more..

Bribery Act expert to attend European conference

12 October 2015

A Partner from City-based solicitors Royds will be addressing a top international conference on the subject of the UK’s Bribery Act.

Read more..
See more articles in News
Events [1]
Article thumbnail

Life after Brexit: the challenges and opportunities facing the UK’s Life Sciences sector

5 December 2018

“The life sciences industry represents one of the dominant economic sectors in the UK.
It brings significant jobs and growth to virtually every region. To retain the UK’s competitive edge in this sector, there is a requirement for sustained effort over a longer period of time”.
Professor Sir John Bell, Regius Professor of Medicine, University of Oxford and Chairman, Office for the Strategic Coordination of Health Research.

Read more..
See more articles in Events
Case Studies [1]

Negotiation, drafting and review of a contract for a new orphan drug

Long standing client from charity sector with a patient data base, came to us with the need for legal advice. It had been approached by a European Pharmaceutical, (EP). EP wanted to have access to our client’s database in order …

Read more..
See more articles in Case Studies
Return to Our People
Read more articles from Claus

View experts by name

View by service and office location

By continuing to browse this site you are agreeing to our use of cookies. Read more